Hennion & Walsh Asset Management Inc. Raises Stock Position in Johnson & Johnson $JNJ

Hennion & Walsh Asset Management Inc. boosted its stake in Johnson & Johnson (NYSE:JNJ) by 6.1% in the fourth quarter, HoldingsChannel reports. The firm owned 41,136 shares of the company’s stock after acquiring an additional 2,382 shares during the period. Hennion & Walsh Asset Management Inc.’s holdings in Johnson & Johnson were worth $8,513,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also added to or reduced their stakes in the stock. SOA Wealth Advisors LLC. grew its holdings in shares of Johnson & Johnson by 0.7% in the third quarter. SOA Wealth Advisors LLC. now owns 7,392 shares of the company’s stock worth $1,371,000 after acquiring an additional 53 shares during the period. Ethos Financial Group LLC lifted its holdings in Johnson & Johnson by 0.6% in the third quarter. Ethos Financial Group LLC now owns 9,110 shares of the company’s stock valued at $1,689,000 after acquiring an additional 53 shares during the period. Pinnacle Holdings LLC lifted its holdings in Johnson & Johnson by 0.5% in the third quarter. Pinnacle Holdings LLC now owns 11,214 shares of the company’s stock valued at $2,079,000 after acquiring an additional 54 shares during the period. Bouchey Financial Group Ltd boosted its position in Johnson & Johnson by 0.8% in the third quarter. Bouchey Financial Group Ltd now owns 7,249 shares of the company’s stock worth $1,344,000 after purchasing an additional 54 shares during the last quarter. Finally, Boltwood Capital Management grew its stake in shares of Johnson & Johnson by 1.3% during the 4th quarter. Boltwood Capital Management now owns 4,263 shares of the company’s stock valued at $882,000 after purchasing an additional 54 shares during the period. 69.55% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on JNJ shares. Barclays increased their price objective on shares of Johnson & Johnson from $217.00 to $234.00 and gave the stock an “equal weight” rating in a research note on Thursday, March 19th. Argus boosted their target price on shares of Johnson & Johnson from $210.00 to $240.00 in a research report on Friday, January 23rd. UBS Group reiterated a “buy” rating on shares of Johnson & Johnson in a research report on Monday, January 5th. Royal Bank Of Canada reiterated an “outperform” rating and set a $255.00 price target on shares of Johnson & Johnson in a research note on Monday. Finally, Wall Street Zen downgraded shares of Johnson & Johnson from a “buy” rating to a “hold” rating in a research report on Saturday, February 14th. One research analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and nine have assigned a Hold rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $236.91.

Trending Headlines about Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Royalty Pharma agreed to co‑fund J&J’s autoimmune candidate JNJ‑4804 with up to $500M, accelerating development while sharing cost/risk — a near‑term financing boost that strengthens J&J’s immunology story and could materially de‑risk future revenue upside. Royalty Pharma and J&J partner to develop autoimmune treatment
• Positive Sentiment: J&J’s recently approved oral psoriasis drug ICOTYDE showed durable 52‑week efficacy and near‑placebo safety in Phase 3/ICONIC data — a potential meaningful new product launch that bolsters immunology growth expectations. Will ICOTYDE’s First‑in‑Class Oral Psoriasis Launch Redefine J&J’s Immunology Narrative?
• Positive Sentiment: Market coverage frames the JNJ‑4804 funding pact and other immunology moves as adding heft to J&J’s growth pipeline — positive sentiment for medium‑term revenue prospects. Johnson & Johnson’s JNJ-4804 Deal Adds Weight To Immunology Story
• Positive Sentiment: An analyst shop (RBC) reaffirmed an outperform rating and set a $255 price target, signaling buy‑side support and limited near‑term upside capture by bulls. Benzinga: RBC Outperform, $255 PT
• Positive Sentiment: J&J presented encouraging randomized Phase 2 data (CONVERGE) for a radiotherapy‑adjunct asset (NBTXR3/JNJ‑1900) at a major conference — supportive for oncology pipeline valuation. NANOBIOTIX Announces Presentation of First Data
• Neutral Sentiment: Valuation and dividend analyses are being debated: some quant work questions whether JNJ remains undervalued after the rally, while other pieces emphasize its dividend‑king status and defensive appeal — these shape investor positioning but don’t change fundamentals immediately. Seeking Alpha: Is the Stock Still Undervalued?
• Neutral Sentiment: Macro risk‑off moves and a broader market rally (U.S. geopolitical headlines) have lifted many stocks; J&J’s low beta/dividend profile makes it a common safe‑haven trade in volatile sessions. Dow Jones Futures: Market Soars As Trump Signals Iran War Exit
• Negative Sentiment: Media pieces (including commentary from Jim Cramer) continue to flag past “free fall” volatility and ongoing litigation exposures, which remain an overhang on sentiment and could cap multiple expansion until legal clarity improves. Jim Cramer Highlights J&J Stock’s Free Fall and Rise

Johnson & Johnson Stock Performance

JNJ opened at $244.48 on Wednesday. The company has a debt-to-equity ratio of 0.48, a quick ratio of 0.77 and a current ratio of 1.03. The stock has a market capitalization of $588.86 billion, a price-to-earnings ratio of 22.12, a PEG ratio of 2.40 and a beta of 0.34. The company has a fifty day moving average of $238.40 and a 200 day moving average of $211.86. Johnson & Johnson has a fifty-two week low of $141.50 and a fifty-two week high of $251.71.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Saturday, January 31st. The company reported $2.46 EPS for the quarter. Johnson & Johnson had a net margin of 28.46% and a return on equity of 33.04%. The business had revenue of $24.28 billion for the quarter. As a group, sell-side analysts forecast that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Tuesday, March 10th. Investors of record on Tuesday, February 24th were given a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a dividend yield of 2.1%. The ex-dividend date was Tuesday, February 24th. Johnson & Johnson’s payout ratio is currently 47.06%.

Insider Buying and Selling

In related news, EVP Timothy Schmid sold 22,623 shares of the stock in a transaction that occurred on Wednesday, February 18th. The stock was sold at an average price of $244.33, for a total transaction of $5,527,477.59. Following the completion of the transaction, the executive vice president directly owned 26,769 shares of the company’s stock, valued at approximately $6,540,469.77. This represents a 45.80% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Vanessa Broadhurst sold 6,197 shares of the firm’s stock in a transaction that occurred on Tuesday, February 17th. The shares were sold at an average price of $243.39, for a total value of $1,508,287.83. Following the transaction, the executive vice president owned 23,003 shares of the company’s stock, valued at $5,598,700.17. This represents a 21.22% decrease in their position. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 30,142 shares of company stock valued at $7,360,528. 0.16% of the stock is owned by corporate insiders.

Johnson & Johnson Company Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.